![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
WY Gao, DG Johns and H Mitsuya
Experimental Retrovirology Section, National Cancer Institute, Bethesda, Maryland 20892.
The effects of hydroxyurea (HU), an inhibitor of ribonucleotide reductase, on the replication of human immunodeficiency virus type 1 (HIV-1) in activated peripheral blood mononuclear cells were studied. The inhibition of HIV-1 replication by HU alone was dose dependent, with a 90% inhibitory concentration of 0.4 mM, a plasma concentration tolerated by patients with oncological diseases. HU at lower concentrations (< 0.1 mM) was found to potentiate the antiviral activity of 2',3'-dideoxyinosine (ddl), 3'-azido-2',3'- dideoxythymidine, and 2',3'-dideoxycytidine against HIV-1, with the potentiation being ddl greater than 3'-azido-2',3'- dideoxythymidine = 2',3'-dideoxycytidine. In the presence of 0.1 mM HU, the 90% inhibitory concentration of ddl was reduced by 6-fold in activated peripheral blood mononuclear cells. The potentiating effect of HU on ddl action was time dependent, with the greatest inhibition of HIV-1 growth being seen when HU was present during and after virus adsorption, i.e., apparently coinciding with the time of proviral DNA synthesis. A brief incubation of activated cells with HU and ddl at low concentrations before virus exposure reduced p24 production by > 50%. Analyses using high performance liquid chromatography and enzymatic assays suggested that the greater degree of potentiation by HU of the action of ddl, compared with the other dideoxynucleosides, is due to the more effective inhibition by HU of dATP synthesis, compared with the synthesis of the other deoxynucleoside triphosphates (dGTP, dTTP, and dCTP). The present study suggests that, for appropriate agents, pharmacological reduction of deoxynucleoside triphosphate levels represents a potential therapeutic approach for inhibition of HIV-1 replication.
This article has been cited by other articles:
|
|
 |
|
  R. M. Oguariri, T. W. Brann, and T. Imamichi Hydroxyurea and Interleukin-6 Synergistically Reactivate HIV-1 Replication in a Latently Infected Promonocytic Cell Line via SP1/SP3 Transcription Factors J. Biol. Chem., February 9, 2007; 282(6): 3594 - 3604. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Rodriguez-Torres, F. J. Torriani, V. Soriano, M. J. Borucki, E. Lissen, M. Sulkowski, D. Dieterich, K. Wang, J.-M. Gries, P. G. Hoggard, et al. Effect of Ribavirin on Intracellular and Plasma Pharmacokinetics of Nucleoside Reverse Transcriptase Inhibitors in Patients with Human Immunodeficiency Virus-Hepatitis C Virus Coinfection: Results of a Randomized Clinical Study Antimicrob. Agents Chemother., October 1, 2005; 49(10): 3997 - 4008. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. de Mendoza, E. Paxinos, P. Barreiro, N. Camino, M. Nunez, and V. Soriano Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations J. Clin. Microbiol., February 1, 2004; 42(2): 862 - 866. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. R. Gwilt, K. K. Manouilov, J. McNabb, and S. S. Swindells Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV-1-Infected Patients J. Clin. Pharmacol., September 1, 2003; 43(9): 1003 - 1007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Mansky, E. Le Rouzic, S. Benichou, and L. C. Gajary Influence of Reverse Transcriptase Variants, Drugs, and Vpr on Human Immunodeficiency Virus Type 1 Mutant Frequencies J. Virol., February 1, 2003; 77(3): 2071 - 2080. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Mansky, D. K. Pearl, and L. C. Gajary Combination of Drugs and Drug-Resistant Reverse Transcriptase Results in a Multiplicative Increase of Human Immunodeficiency Virus Type 1 Mutant Frequencies J. Virol., August 12, 2002; 76(18): 9253 - 9259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Balzarini, M.-J. Camarasa, M.-J. Perez-Perez, A. San-Felix, S. Velazquez, C.-F. Perno, E. De Clercq, J. N. Anderson, and A. Karlsson Exploitation of the Low Fidelity of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase and the Nucleotide Composition Bias in the HIV-1 Genome To Alter the Drug Resistance Development of HIV J. Virol., July 1, 2001; 75(13): 5772 - 5777. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. G. Hoggard, J. Lloyd, S. H. Khoo, M. G. Barry, L. Dann, S. E. Gibbons, E. G. Wilkins, C. Loveday, and D. J. Back Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents Antimicrob. Agents Chemother., March 1, 2001; 45(3): 976 - 980. [Abstract] [Full Text]
|
|
|
|
 |
|
 C.A. HART, N.J. BEECHING, and B.I. DUERDEN Infections in AIDS: Proceedings of the Sixth Liverpool Tropical School Bayer Symposium on Microbial Diseases held on 6 February 1999 J. Med. Microbiol., November 1, 2000; 49(11): 947 - 967. [Full Text] [PDF]
|
|
|
|
|
|
J. Neyts and E. De Clercq Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs Antimicrob. Agents Chemother., December 1, 1999; 43(12): 2885 - 2892. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. N. Mayhew, J. D. Phillips, R. N. Greenberg, N. J. Birch, H. L. Elfordf, and V. S. Gallicchio In Vivo and In Vitro Comparison of the Short-Term Hematopoietic Toxicity Between Hydroxyurea and Trimidox or Didox, Novel Ribonucleotide Reductase Inhibitors with Potential Anti-HIV-1 Activity Stem Cells, November 1, 1999; 17(6): 345 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
S. Palmer, R. W. Shafer, and T. C. Merigan Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates Antimicrob. Agents Chemother., August 1, 1999; 43(8): 2046 - 2050. [Abstract] [Full Text]
|
|
|
|
 |
|
 W.-Y. Gao, D. G. Johns, M. Tanaka, and H. Mitsuya Suppression of Replication of Multidrug-Resistant HIV Type 1 Variants by Combinations of Thymidylate Synthase Inhibitors with Zidovudine or Stavudine Mol. Pharmacol., March 1, 1999; 55(3): 535 - 540. [Abstract] [Full Text]
|
|
|
|
|
|
J. G. Julias and V. K. Pathak Deoxyribonucleoside Triphosphate Pool Imbalances In Vivo Are Associated with an Increased Retroviral Mutation Rate J. Virol., October 1, 1998; 72(10): 7941 - 7949. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
